UY39593A - Tratamiento para tumores sólidos malignos - Google Patents

Tratamiento para tumores sólidos malignos

Info

Publication number
UY39593A
UY39593A UY0001039593A UY39593A UY39593A UY 39593 A UY39593 A UY 39593A UY 0001039593 A UY0001039593 A UY 0001039593A UY 39593 A UY39593 A UY 39593A UY 39593 A UY39593 A UY 39593A
Authority
UY
Uruguay
Prior art keywords
solid tumors
treatment
malignant solid
subject
malignant
Prior art date
Application number
UY0001039593A
Other languages
English (en)
Spanish (es)
Inventor
Gajanan Bhat
Lyndah Dreiling
Sribalaji Lakshmikanthan
A Barrett John
Francois Lebel
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of UY39593A publication Critical patent/UY39593A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001039593A 2020-12-29 2021-12-28 Tratamiento para tumores sólidos malignos UY39593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063199445P 2020-12-29 2020-12-29
US202163166748P 2021-03-26 2021-03-26

Publications (1)

Publication Number Publication Date
UY39593A true UY39593A (es) 2022-07-29

Family

ID=82259660

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039593A UY39593A (es) 2020-12-29 2021-12-28 Tratamiento para tumores sólidos malignos

Country Status (3)

Country Link
TW (1) TW202237122A (zh)
UY (1) UY39593A (zh)
WO (1) WO2022147150A1 (zh)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210145161A (ko) * 2019-03-29 2021-12-01 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Her2 엑손 21 삽입물을 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
KR20210149103A (ko) * 2019-03-29 2021-12-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 또는 her2 엑손 20 삽입을 지니는 암 세포에 대한 항종양 활성을 갖는 화합물
WO2022026442A1 (en) * 2020-07-27 2022-02-03 Spectrum Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with poziotinib

Also Published As

Publication number Publication date
WO2022147150A1 (en) 2022-07-07
TW202237122A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
CL2021002267A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945)
CO2021015318A2 (es) Compuestos y métodos para el tratamiento de covid-19
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
AR101740A1 (es) Terapia de combinación y composiciones
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
WO2018102687A3 (en) Combination therapy for treating cancer
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2023000857A1 (es) Inhibidores line-1 para tratar la enfermedad
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
BR112021020962A2 (pt) Métodos de tratamento de prurido
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
UY39593A (es) Tratamiento para tumores sólidos malignos
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres
AR122301A1 (es) Métodos para tratar los tumores del estroma gastrointestinal
AR117290A1 (es) Enfoque de tratamiento de cáncer mediante inmunomodulación
AR124521A1 (es) Tratamiento para tumores sólidos malignos